[Medication of the month. Febuxostat (Adenuric)]
Service de Néphrologie-Dialyse-Transplantation, Université de Liège, CHU de Liège, Belgique.Revue médicale de Liège 04/2012; 67(4):202-9.
Gout is a rheumatologic disease due to the deposition of urate (the catabolite of purines) crystals within joints. Prevalence of the disease is high. Potential articular and nephrological complications are numerous. Therefore, a chronic, preventive and effective therapy is required in specific patients. Dietary changes are frequently insufficient and urate-lowering therapy is thus necessary, like uricosuric or xanthine oxydase inhibitors. The objective of these therapies is to lower serum urate levels below 6 mg/dL. The xanthine oxydase inhibitor allopurinol is still the most used in the context of gout prevention. However, allopurinol tolerance and efficacy are far from optimal. Now, a new therapy is available in Belgium, the febuxostat. Febuxostat is a new xanthine oxidase inhibitor.Tolerance and therapeutic effect seem better compared to allopurinol. In this article, we review pharmacological data about this new treatment. We also review the most important clinical trials underlining strengths and limitations of febuxostat.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.